Biotalk Episode 5: A Conversation with Onaiza Cadoret-Manier

On this episode of Biotalk, Locust Walk welcomes Onaiza Cadoret-Manier, Executive Vice President, Chief Global Product Strategy & Operations Officer at Ionis Pharmaceuticals to the podcast. Prior to Ionis, Onaiza was the chief commercial officer for Grail Biosciences, an early detection genomics company, where she developed the commercial strategy and business model. Onaiza discusses her journey into the biotech industry and Ionis, challenges overcome while shifting from an R&D focus to commercialization, and her perspective and outlook on biotech today. Locust Walk is happy to speak with you further if you have any questions about this episode or if we can be helpful to guide your organization through the current market environment. Timestamps:    1:12: How did you find yourself in the biotech industry?    2:12: Prior to starting at Ionis, you held roles at Grail, Genentech, Pfizer and Amylin. What is a key takeaway you have from each of those experiences?  6:12: What were some challenges you had to overcome when shifting from an R&D focus to commercialization? How has that evolved over time with Ionis?  11:16: Do you have any advice for how to think about the process for picking the best targets for a company, especially if they differing levels of resource?  13:35: What excites you about the pipeline or innovations that you’re seeing either internal to Ionis or externally?  16:54: Is it true that Ionis is looking to both buy and sell?  18:28: COVID had a profound effect on the industry, which experienced a huge run followed by an even bigger downturn. What’s your perspective on the industry today? What’s your outlook for 2023?   32:36: